Results 241 to 250 of about 5,496,645 (302)
Erratum: Relationship Between Netrin-1 Staining and Neoadjuvant Treatment Response in HER2-Positive Locally Advanced Breast Cancer [Corrigendum]. [PDF]
Cancer Manag Reseuropepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Advances in Radiotherapy for Breast Cancer
Surgical Oncology Clinics of North America, 2023Breast cancer is the most prevalent cancer in women, and the second leading cause of cancer death in women in the United States. Radiation therapy is an important component in the multimodal management of breast cancer, including early stage and locally advanced breast cancers, as well as metastatic cases.
Rituraj, Upadhyay, Jose G, Bazan
openaire +2 more sources
Trilostane in advanced breast cancer
Expert Opinion on Pharmacotherapy, 2006Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years. However, some patients acquire resistance to these treatments and, at present, further endocrine treatment is achieved by merely substituting the current medication ...
John R, Puddefoot +2 more
openaire +2 more sources
Hypophysectomy in advanced breast cancer
The American Journal of Surgery, 1965THERE is undisputed evidence that the administration of steroid hormones or deprivation of hormone-producing tissues favorably modifies the anticipated behavior of advanced breast cancer. Extensive reviews have demonstrated the improvement that may be attained in selected patients after castration or adrenalectomy and the administration of estrogenic ...
B J, KENNEDY, L, FRENCH
openaire +2 more sources
Locally advanced breast cancer
Current Opinion in Obstetrics and Gynecology, 2006The management of locally advanced breast cancer requires a combined-modality treatment approach involving surgery, radiotherapy and systemic therapy. In this paper, we review clinical and experimental studies in order to evaluate how basic and clinical research in locally advanced breast cancer has progressed in the past year.
Barni S, Mandala' M
openaire +3 more sources
Advances in the Treatment of Breast Cancer
Clinical Pharmacology & Therapeutics, 2007Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer-related deaths in this population. This review highlights how the use of a multidisciplinary approach to the management of diseases of the breast and the introduction of novel systemic therapies have improved the quality of life and survival ...
S, Moulder, G N, Hortobagyi
openaire +2 more sources
Locally advanced breast cancer
Oncology Reports, 1996In vitro studies suggest p53 and bcl-2 may be important in the apoptotic response to irradiation, and that rapidly proliferating cells are more sensitive to radiotherapy. The clinical relevance of biological factors in predicting radiotherapy response was investigated in 62 patients with locally advanced breast cancer.
P, Willsher +5 more
openaire +2 more sources
Zoladex in Advanced Breast Cancer
Hormone Research, 2008In the treatment of 53 premenopausal patients with advanced breast cancer, the LHRH analogue, Zoladex (goserelin), produced a response rate similar to that of surgical oophorectomy. Endocrinologically, Zoladex caused castrate levels of serum oestradiol and progesterone except in a small number of patients, where intermittent, suppressed peaks of ...
J F, Robertson +3 more
openaire +2 more sources
LOCALLY ADVANCED BREAST CANCER
Hematology/Oncology Clinics of North America, 1999The multidisciplinary management of patients with locally advanced breast cancer (LABC) has evolved over the last three decades. The introduction of chemotherapy (CT) and endocrine therapy in conjunction with surgery and radiation therapy (XRT) have changed the natural history of this disease.
F J, Esteva, G N, Hortobagyi
openaire +2 more sources
The Treatment of Advanced Breast Cancer
The American Journal of Nursing, 1962of reigning supreme. In women throughout the United States, the breast is the most frequent single organ site of malignancy. Breast cancer is the leading cause of death of women in the prime of life, between 40 and 60 years of age. The incidence of this disease is incredibly high and shows no sign of declining.
openaire +2 more sources